The role and clinical significance of DNA damage response and repair pathways in primary brain tumors

Cell and Bioscience

Volumn 3, Issue 1, 2013, Pages

  Santivasi, Wil L ^a   Xia, Fen ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Brain tumor; DNA damage; DNA repair; Homologous recombination (HR); Non homologous end joining (NHEJ)

Indexed keywords

EID: 84873621891     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-3-10     Document Type: Review

References (57)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Canc J Clin 2012, 62:10-29.
2. Ohgaki H. Epidemiology of brain tumors. Cancer Epidemiology 2009, 323-342. New York: Humana Press, Verma M, Totowa NJ, [Walker JM (Series Editor): Methods in Molecular Biology, vol 472.].
3. CBTRUS Statistical Report Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 (March 23, 2012 Revision) 2012, Hinsdale, IL: Source: Central Brain Tumor Registry of the United States, CBTRUS Statistical Report.
4. Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2009, 17:417-421.
5. Batchelor T, Curry WT. Clinical manifestations and initial surgical approach to patients with malignant gliomas. UpToDate 2012, Philadelphia: Wolters Kluwer Health, Loeffler JS, Waltham MA.
6. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Canc J Clin 2010, 60:166-193.
7. Lawrence YR, Li XA, el Naga I, Hahn CA, Marks LB, Merchant TE, Dicker AP. Radiation dose-volume effects in the brain. Int J Rad Onc 2010, 76:s20-s27.
8. Gu J, Liu Y, Kyritsis AP, Bondy ML. Molecular epidemiology of primary brain tumors. Neurotherapeutics 2009, 6:427-435. 10.1016/j.nurt.2009.05.001, 19560733.
9. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Canc Res 2009, 7:989-999.
10. Lawson AR, Hindley GF, Forshew T, Tatevossian RG, Jamie GA, Kelly GP, Neale GA, Ma J, Jones TA, Ellison DW, Sheer D. RAF gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence homology. Genome Res 2011, 21:505-514. 10.1101/gr.115782.110, 3065698, 21393386.
11. Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst) 2008, 7:1765-1771.
12. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell 2008, Oxford: Garland Science, 5.
13. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010, 11:196-207. 10.1038/nrm2851, 3261768, 20177395.
14. Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003, 22:5784-5791. 10.1038/sj.onc.1206678, 12947386.
15. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003, 22:5612-5621. 10.1093/emboj/cdg541, 213795, 14532133.
16. Miyagawa K. Clinical relevance of the homologous recombination machinery in cancer therapy. Canc Sci 2008, 99:187-194.
17. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Brit J Canc 2008, 98:523-528.
18. Zou Y, Liu Y, Wu X, Shell SM. Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses. J Cell Phys 2006, 208:267-273.
19. Brenneman MA, Wagener BM, Miller CA, Allen C, Nickoloff JA. XRCC3 controls the fidelity of homologous recombination. Mol Cell 2002, 10:387-395. 10.1016/S1097-2765(02)00595-6, 12191483.
20. Maloisel L, Fabre F, Gangloff S. DNA polymerase delta is preferentially recruited during homologous recombination to promote heteroduplex DNA extension. Mol Cell Biol 2008, 28:1373-1382. 10.1128/MCB.01651-07, 2258756, 18086882.
21. Goetz JD, Motycka TA, Han M, Jasin M, Tomkinson AE. Reduced repair of DNA double-strand breaks by homologous recombination in a DNA ligase I-deficient human cell line. DNA Repair (Amst) 2005, 4:649-654.
22. Zhou K, Liu Y, Zhang H, Liu H, Fan W, Zhong Y, Xu Z, Jin L, Wei Q, Huang F, Lu D, Zhou L. XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study. Int J Canc 2009, 124:2948-2953.
23. Kiuru A, Lindholm C, Heinavaara S, Ilus T, Jokinen P, Haapasalo H, Salminen T, Christensen HC, Feychting M, Johansen C, Lonn S, Malmer B, Schoemaker MJ, Swerdlow AJ, Auvinen A. XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neuro Oncol 2008, 88:135-142.
24. Wang L, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, Pudavalli V, Levin VA, Yung WK, Wei Q. Polymorphisms of DNA repair genes and risk of glioma. Canc Res 2004, 64:5560-5563.
25. Chang JS, Yeh RF, Wiencke JK, Wiemels JL, Smirnov I, Pico AR, Tihan T, Patoka J, Miike R, Sison JD, Rice T, Wrensch MR. Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Canc Epidemiol Biomarkers Prev 2008, 17:1368-1373.
26. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004, 26:882-893. 10.1002/bies.20085, 15273990.
27. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, Chung JH, Powell SN, Xia F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004, 24:708-718. 10.1128/MCB.24.2.708-718.2004, 343805, 14701743.
28. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25:5864-5874. 10.1038/sj.onc.1209874, 16998501.
29. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921. 10.1038/nature03445, 15829967.
30. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
31. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008, 27:1368-1377. 10.1038/emboj.2008.61, 2374839, 18388863.
32. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmicheal J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
33. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011, 22:268-279. 10.1093/annonc/mdq322, 20643861.
34. Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 2011, 13:442-449. 10.1007/s11912-011-0193-9, 21913063.
35. Wang H, Yang ES, Jiang J, Nowsheen S, Xia F. DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation. Canc Res 2010, 70:6258-6267.
36. Li L, Wang H, Yang ES, Arteaga CL, Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Canc Res 2008, 68:9141-9146.
37. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003, 4:712-720. 10.1038/nrm1202, 14506474.
38. Shibata A, Conrad S, Birraux J, Geuting V, Barton O, Ismail A, Kakarougkas A, Meek K, Taucher-Scholz G, Lobrich M, Jeggo PA. Factors determining DNA double-strand break repair pathway choice in G2 phase. EMBO J 2011, 30:1079-1092. 10.1038/emboj.2011.27, 3061033, 21317870.
39. Weterings E, Chen DJ. The endless tale of non-homologous end-joining. Cell Res 2008, 18:11-124.
40. Spagnolo L, Rivera-Calzada A, Pearl LJ, Llorca O. Three-dimensional structure of the human DNA-PKcs/Ku7-/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell 2006, 22:511-519. 10.1016/j.molcel.2006.04.013, 16713581.
41. Moll U, Lau R, Sypes MA, Gupta MM, Anderson CW. DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene 1999, 18:3114-3126. 10.1038/sj.onc.1202640, 10340383.
42. Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002, 108:781-794. 10.1016/S0092-8674(02)00671-2, 11955432.
43. Suzuki K, Kodama S, Watanabe M. Recruitment of ATM protein to double strand DNA irradiated with ionizing radiation. J Biol Chem 1999, 274:25571-25575. 10.1074/jbc.274.36.25571, 10464290.
44. Yamtich J, Sweasy JB. DNA polymerase family X: function, structure, and cellular roles. Biochim Biophys Acta 2010, 1804:1136-1150. 10.1016/j.bbapap.2009.07.008, 2846199, 19631767.
45. Wilson TE, Grawunder U, Lieber MR. Yeast DNA ligase IV mediates non-homologous DNA end joining. Nature 1997, 388:495-498. 10.1038/41365, 9242411.
46. Liu Y, Zhou K, Zhang H, Shugart YY, Chen L, Xu Z, Shong Y, Liu H, Jin L, Wei Q, Huang F, Lu D, Zhou L. Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma. Hum Mutat 2008, 29:381-389. 10.1002/humu.20645, 18165945.
47. Liu Y, Zhang H, Zhou K, Chen L, Xu Z, Zhong Y, Liu H, Li R, Shugart YY, Wei Q, Jin L, Huang F, Lu D, Zhou L. Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma. Carcinogenesis 2007, 28:1906-1913. 10.1093/carcin/bgm073, 17389609.
48. Burma S, Chen DJ. Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair 2004, 3:909-918. 10.1016/j.dnarep.2004.03.021, 15279776.
49. Iliakis G, Wang H, Perrault AR, Boecker W, Rosidi B, Windhofer F, Wu W, Guan J, Terzoudi G, Pantelias G. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res 2004, 104:14-20. 10.1159/000077461, 15162010.
50. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116:1175-1186. 10.1242/jcs.00384, 3006448, 12615961.
51. Yang ES, Wang H, Jiang G, Nowsheen S, Fu A, Hallahan DE, Xia F. Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. J Clin Invest 2009, 119:1124-1135. 10.1172/JCI34051, 2673855, 19425167.
52. Yazlovitskaya EM, Edwards E, Thotala D, Fu A, Osusky KL, Whetsell WO, Boone B, Shinohara ET, Hallahan DE. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Canc Res 2006, 66:11179-11186.
53. Yang ES, Nowsheen S, Wang T, Thotala DK, Xia F. Glycogen synthase kinase 3β inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons. Neuro Oncol 2011, 13:459-470. 10.1093/neuonc/nor016, 3093336, 21398658.
54. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 4:339-345.
55. Knobbe CB, Merlo A, Reifenberger G. Pten signaling in gliomas. Neuro Oncol 2002, 4:196-211. 1920635, 12084351.
56. Paez J, Sellers W. PI3K/PTEN/Akt pathway: a critical mediator of oncogenic signaling. Signal Transduction in Cancer 2004, 145-167. Boston, MA: Springer Press, Walker JM.
57. Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P, Hemmings BA, Merlo A, Lino MM. GSK3β Regulates Differentiation and Growth Arrest in Glioblastoma. PLoS One 2009, 4:e7443. 10.1371/journal.pone.0007443, 2757722, 19823589.